北大医药(000788) - 2022 Q1 - 季度财报

Financial Performance - Revenue for Q1 2022 was ¥482,036,482.63, a decrease of 5.91% compared to ¥512,301,458.44 in Q1 2021[3] - Net profit attributable to shareholders was ¥11,872,378.05, down 48.38% from ¥22,998,217.21 in the same period last year[3] - Basic earnings per share decreased by 48.45% to ¥0.0199 from ¥0.0386 in Q1 2021[3] - Total operating revenue for Q1 2022 was CNY 482,036,482.63, a decrease of 5.9% compared to CNY 512,301,458.44 in the previous year[20] - Net profit for Q1 2022 was CNY 11,871,474.86, a decline of 48.3% from CNY 22,997,368.17 in Q1 2021[21] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.0199, down from CNY 0.0386 in the previous year[22] Cash Flow and Assets - Net cash flow from operating activities improved by 74.63%, reaching -¥3,878,417.69 compared to -¥15,287,950.66 in Q1 2021[3] - Cash flow from operating activities for Q1 2022 showed a net outflow of CNY 3,878,417.69, an improvement from a net outflow of CNY 15,287,950.66 in Q1 2021[24] - Cash and cash equivalents at the end of Q1 2022 were CNY 343,435,836.55, down from CNY 351,310,626.07 at the end of Q1 2021[24] - The company's cash and cash equivalents were CNY 440,612,457.89, down from CNY 446,260,598.94 at the beginning of the year[16] - As of March 31, 2022, the total current assets amounted to CNY 2,151,498,007.79, a decrease from CNY 2,170,219,968.08 at the beginning of the year, representing a decline of approximately 0.86%[17] Expenses and Liabilities - Total operating costs for Q1 2022 were CNY 468,535,025.64, down 3.2% from CNY 484,059,251.82 in the same period last year[20] - R&D expenses increased by 70.67% to ¥2,236,380.58, reflecting higher investment in research and development[7] - Research and development expenses increased to CNY 2,236,380.58 in Q1 2022, compared to CNY 1,310,327.26 in the same period last year, reflecting a focus on innovation[20] - Sales expenses decreased significantly to CNY 135,390,427.74 in Q1 2022 from CNY 179,418,259.20 in Q1 2021, indicating cost control measures[20] - The total liabilities decreased to CNY 1,175,123,350.16 from CNY 1,206,677,909.88, indicating a reduction of about 2.6%[18] Shareholder Information - Shareholder equity attributable to shareholders increased by 0.89% to ¥1,352,023,044.58 from ¥1,340,151,569.72 at the end of the previous year[3] - The total equity attributable to shareholders of the parent company was CNY 1,352,023,044.58, an increase from CNY 1,340,151,569.72 year-over-year[21] - The number of ordinary shareholders at the end of the reporting period was 101,076[9] Tax and Subsidies - The company reported a significant reduction in income tax expenses, down 60.23% to ¥2,178,557.71 due to decreased profitability[7] - The company received government subsidies amounting to ¥181,377.81 during the reporting period[6] Regulatory and Legal Matters - The company received approval from the National Medical Products Administration for the chemical drug "Trimebutine Hydrochloride Sustained-Release Tablets" on January 11, 2022[11] - The company signed a supplementary agreement to mitigate guarantee risks with Southwest Synthetic Pharmaceutical Group, achieving substantial progress in risk resolution[12] - The company is in the process of resolving a construction contract dispute with Jiangsu Huajian Construction Co., achieving substantial progress in risk mitigation[14] Market Activity - The company disclosed a significant fluctuation in stock prices, with cumulative price deviation exceeding 20% over several trading days in March 2022[14] - The company is expected to engage in daily related transactions with China Ping An and its affiliates, as approved by the board of directors[11] Audit and Reporting - The first quarter report for 2022 has not been audited[25] - The report was released by the Board of Directors on April 29, 2022[26]